Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

4.54EUR
11:11am BST
Change (% chg)

€0.00 (+0.04%)
Prev Close
€4.53
Open
€4.57
Day's High
€4.58
Day's Low
€4.52
Volume
21,067
Avg. Vol
189,150
52-wk High
€11.40
52-wk Low
€4.33

Select another date:

Tue, Apr 17 2018

BRIEF-Reg-Innate Pharma Aacr 2018, New Preclinical Data Further Support Ongoing Programs

* REG-INNATE PHARMA : AACR 2018, NEW PRECLINICAL DATA FURTHER SUPPORT ONGOING PROGRAMS Source text for Eikon: Further company coverage:

BRIEF-Innate Pharma Announces Its Partner Medimmune Expands Colorectal Cancer Patient Cohort In A Phase I Trial

* INNATE PHARMA SA - PARTNER MEDIMMUNE EXPANDS COLORECTAL CANCER PATIENT COHORT IN ONGOING PHASE I TRIAL EVALUATING MONALIZUMAB IN COMBINATION WITH IMFINZI® (DURVALUMAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Innate Pharma Expands mCRC Cohort In Phase I Trial Evaluating Monalizumab With Imfinzi

* REG-INNATE PHARMA : EXPANSION OF MCRC COHORT IN PHASE I TRIAL EVALUATING MONALIZUMAB WITH IMFINZI

BRIEF-Innate Pharma FY Net Results Swings To Loss Of 48.4‍​ Million Euros

* FY REVENUE AND OTHER INCOME EUR 44.0‍​ MILLION VERSUS EUR 65.7 MILLION YEAR AGO

BRIEF-Innate Pharma Appoints Jean-Yves Blay To Its Supervisory Board

* INNATE PHARMA SA - JEAN-YVES BLAY APPOINTED TO INNATE PHARMA SUPERVISORY BOARD Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Innate Pharma And Medimmune Enter Clinical Trial Collaboration

* INNATE PHARMA AND MEDIMMUNE ENTER CLINICAL TRIAL COLLABORATION

Select another date: